An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients

Annals of Oncology

Volumn 17, Issue 7, 2006, Pages 1146-1151

  Palmieri, S ^a   D'Arco, A M ^b   Celentano, M ^a   Mele, G ^a   Califano, C ^b   Pollio, F ^a   D'Amico, M R ^a   Ferrara, Felicetto ^a,c  

^a CARDARELLI HOSPITAL   (Italy)

^b Umberto i Hospital   (Italy)

^c NONE   (Italy)

Author keywords

Acute myeloid leukemia; Antecedent MDS; Elderly patients; Prognostic relevance

Indexed keywords

AMINOTRANSFERASE; BUSULFAN; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; CARDIOTOXICITY; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; TUMOR LYSIS SYNDROME;

EID: 33745601122     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl083     Document Type: Article

References (31)

1. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004; 5: 443-450.
2. Schiffer CA. Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia. New Engl J Med 2003; 349: 727-729.
3. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
4. Pinto A, Zagonel V, Ferrara F. Acute myeloid leukaemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol 2001; 39: 275-287.
5. Wahlin A, Markevarn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001; 115: 25-33.
6. Tallman MS, Gilliland DG, Rowe JM. Drug therapy in acute myeloid leukaemia. Blood 2005; 106: 1154-1163.
7. Ferrara F, Palmieri S,Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukaemia. Haematologica 2004; 89: 998-1008.
8. Chen CC, Yang CF, Yang MH et al. Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. Ann Oncol 2005; 16: 1366-1373.
9. Gupta V, Chun K, Yi QL et al. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 2005; 103: 2082-2090.
10. Grigg AP, Reynolds J, McQuillan A et al. Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine. Leuk Lymphoma 2005; 46: 367-375.
11. Behringer B, Pitako JA, Kunzmann R et al. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: A single-center retrospective study. Ann Hematol 2003; 82: 381-389.
12. Iwakiri R, Ohta M, Mikoshiba M et al. Prognosis of elderly patients with acute myelogenous leukemia: Analysis of 126 AML cases. Int J Hematol 2002; 75: 45-50.
13. Rowe JM, Neuberg D, Friedenberg W et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: A trial by the Eastern Cooperative Oncology Group. Blood 2004; 103: 479-485.
14. Witz F, Sadoun A, Perrin MC et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1998; 91: 2722-2730.
15. Goldstone AH, Burnett AK, Wheatley K et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302-1311.
16. Ferrara F, D'Arco AM, De Simone M et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia. Haematologica 2005; 90: 776-784.
17. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
18. Ferrara F, Morabito F, Martino B et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-transretinoic acid and chemotherapy. J Clin Oncol 2000; 18: 1295-1300.
19. Grimwade D, Walker H, Harrison G et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-1320.
20. WHO Handbook for Reporting Results of Cancer Treatment, Vol. 38. Geneva: World Health Organization 1979.
21. Cheson BD, Bennett JM, Kopecky KJ et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649
22. Ferrara F, Palmieri S, Annunziata M et al. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation. Bone Marrow Transplant 2004; 34: 573-576.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
24. Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid eukemia. A report of the French - American - British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
25. Estey EH. How I treat older patients with AML. Blood 2000; 96: 1670-1673.
26. Rathnasabapathy R, Lancet JE. Management of acute myelogenous leukemia in the elderly. Cancer Control 2003; 10: 469-477.
27. Mengis C, Aebi S, Tobler A et al. Assessment of differences in patient populations selected for exclusion from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 2003; 21: 3933-3939.
28. Keating S, Suciu S, de Witte T et al. The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: Results of the EORTC-GIMEMA AML-10 trial. Leukemia 2003; 17: 60-67.
29. Visani G, Lemoli RM, Tosi P et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105: 775-779.
30. Ferrara F, Palmieri S, Pocali B et al. De novo acute myeloid leukemia with multilineage dysplasia: Treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). Eur J Haematol 2002; 68: 203-209.
31. Pagano L, Pulsoni A, Vignetti M et al. Secondary acute myeloid leukaemia: Results of conventional treatments. Experience of GIMEMA trials. Ann Oncol 2005; 16: 228-233.